MDT

86.14

+1.4%↑

115.43

+2.77%↑

VEEV

175.71

+1.44%↑

HQY

83.11

+1.5%↑

CSBR

5.7

+0.88%↑

MDT

86.14

+1.4%↑

115.43

+2.77%↑

VEEV

175.71

+1.44%↑

HQY

83.11

+1.5%↑

CSBR

5.7

+0.88%↑

MDT

86.14

+1.4%↑

115.43

+2.77%↑

VEEV

175.71

+1.44%↑

HQY

83.11

+1.5%↑

CSBR

5.7

+0.88%↑

MDT

86.14

+1.4%↑

115.43

+2.77%↑

VEEV

175.71

+1.44%↑

HQY

83.11

+1.5%↑

CSBR

5.7

+0.88%↑

MDT

86.14

+1.4%↑

115.43

+2.77%↑

VEEV

175.71

+1.44%↑

HQY

83.11

+1.5%↑

CSBR

5.7

+0.88%↑

Inicio・Lista de Acciones・BioNTech SE ADR

BioNTech SE ADR

Abierto

SectorSanidad

89.55 3.29

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

86.63

Máximo

90.11

Métricas clave
By Trading Economics
Ingresos	-269M -302M
Ventas	-620M 899M
Margen de beneficios	-33.613
Empleados	7,807
EBITDA	-217M -67M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+60.7% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-3.4B 22B
Apertura anterior	86.26
Cierre anterior	89.55

Noticias sobre sentimiento de mercado

By Acuity

89%

11%

325 / 349 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

92.4 / 103.5 Soporte y Resistencia

BioNTech SE ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 jun 2025, 11:48 UTC

Principales Movimientos del Mercado

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

10 mar 2026, 12:50 UTC

Ganancias

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

10 mar 2026, 11:18 UTC

Ganancias

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

4 ago 2025, 14:14 UTC

Ganancias

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped. -- Barrons.com

4 ago 2025, 11:59 UTC

Ganancias

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

12 jun 2025, 14:20 UTC

Adquisiciones, fusiones, absorciones

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 jun 2025, 13:34 UTC

Acciones populares

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

10 jun 2025, 12:18 UTC

Ganancias

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

20 may 2025, 14:46 UTC

Adquisiciones, fusiones, absorciones

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

5 may 2025, 15:13 UTC

Charlas de Mercado

Ganancias

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

Comparación entre iguales

Cambio de precio

BioNTech SE ADR previsión

Precio Objetivo

By TipRanks

60.7% repunte

Estimación a 12 Meses

Media 137 USD 60.7%

Máximo 171 USD

Mínimo 94 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioNTech SE ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

Comprar

Mantener

Vender

De acuerdo con 16 analistas que ofrecen calificaciones bursátiles a para BioNTech SE ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

92.4 / 103.5Soporte y Resistencia

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

325 / 349 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac